At the American Thoracic Society annual meeting, held in Toroto, Canada, Amikacin Inhale, currently being studied for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients, achieved over 1,000 times greater lung exposure to the commonly-used antibiotic amikacin than the intravenous route of administration.
Co-developed by Germany's Bayer and USA-based Nektar Therapeutics, the agent achieved a mean peak tracheal aspirate of amikacin after use once every 12 hours of 16,212 +/- 3,675 mcg/mL vs 14 +/- 4.2 mcg/mL after intravenous administration (15mg/kg per day). After Amikacin Inhale use, peak serum levels of amikacin were 3.2 +/- 0.5mcg/mL vs 47 +/- 4.2 mcg/mL after IV administration. On average, 43% of the dose was delivered to the lungs using the hand-held system with a comparable low systemic exposure, the firms noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze